Ganirelix – GnRH Antagonist Peptide – High Purity 99.53% – GMP Manufacturer

描述

Ganirelix is a synthetic decapeptide that functions as a competitive and selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR). By blocking the binding of endogenous GnRH, Ganirelix prevents the release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary—a critical mechanism in reproductive endocrinology.

Ganirelix is crucial in controlled ovarian stimulation models, fertility intervention studies, and investigations into hypothalamic–pituitary–gonadal (HPG) axis modulation. Its GnRH-blocking properties allow tight control over gonadotropin surge, making it a key tool in both in vitro and in vivo studies on reproductive hormone regulation.

Manufactured under strict GMP standards with a verified 99.53% purity, Ganirelix ensures lot-to-lot consistency. It is supplied as a lyophilized peptide powder with a full Certificate of Analysis, enabling reproducible experimental design and regulatory-ready documentation.

Product Specifications

Mechanism of Action & Research Applications

Ganirelix binds to GnRH receptors on pituitary gonadotrophs, inhibiting signaling cascades that would normally lead to LH and FSH secretion. This action suppresses gonadotropin levels without triggering the initial hormone flare caused by GnRH agonists.

Key Research Areas:

1. Fertility & Assisted Reproductivity Protocols

   • Enables controlled cycle models by preventing LH surges that cause premature ovulation in ovarian stimulation.

2. Endocrine Axis Modulation

   • Used in studies dissecting feedback loops and hormone pulsatility in HPG axis research.

3. Contraceptive Modeling

   • Ganirelix serves as a basis for evaluating GnRH antagonist-based contraceptives in animal models.

4. Hormone-Driven Disease Models

   • It’s valuable in research on hormone-dependent cancers and endocrine manipulation in cancer therapeutics.

5. In Vitro Gonadotroph Studies

   • Used to delineate GnRHR signaling via cell lines or primary pituitary cultures.

Development & Formulation Notes

• Reconstitution: Dissolve in sterile water or buffer; common stock: 1 mg/mL. Aliquot to minimize freeze–thaw cycles.

• Dosing: Rodent models typically use 50–300 ?g/day; dose according to species and study design.

• Stability: Reconstituted stocks stable short-term (4–8 °C) for several days; freeze long-term at ?80 °C. Validate concentration via UV or peptide assay.

• Combination Studies: Ideal for combination with hormone analyses, GnRH pulse generators, or steroid effectors.

  

Disclaimer

Ganirelix is strictly for laboratory research use only. It is not approved for clinical, diagnostic, or therapeutic applications. Users must comply with institutional biosafety and regulatory protocols. Described uses apply solely in preclinical or in vitro contexts.

Keywords

Ganirelix; GnRH antagonist; LH suppression peptide; FSH blockade; fertility research peptide; reproductive endocrinology; GMP peptide; CAS 124904-93-4; HPG axis research tool; decapeptide antagonist.